文献速递白血病

低甲基化药物联合维奈克拉治疗新诊断不适合强化疗及复发/难治性儿童、青少年和年轻成人急性髓系白血病患者的临床结局

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
PubMed 文献 · Br J Haematol · 2024-07-31

该回顾性研究分析了辛辛那提儿童医院医疗中心27例接受低甲基化药物(HMA)联合维奈克拉(VEN)治疗的儿童及青少年/年轻成人(AYA)急性髓系白血病(AML)患者,共30个疗程。总完全缓解(CR)/CR伴血细胞计数不完全恢复(CRi)率为73%,其中新诊断组89%、复发/难治组67%。研究支持HMA+VEN在该人群中的安全性和有效性,但需进一步研究确定最佳维奈克拉剂量、化疗组合及药代动力学。

要点

  • 27例儿童/AYA AML患者接受30个HMA+VEN疗程,总CR/CRi率73%,MRD阴性率77%。
  • 新诊断组(n=9)CR/CRi率89%,复发/难治组(n=21)CR/CRi率67%。
  • 3-4级毒性包括中性粒细胞减少(90%)、贫血(64%)、血小板减少(64%)和发热性中性粒细胞减少(44%)。

核心结论

  • 研究结果支持HMA+VEN在儿童/AYA AML中的安全性和有效性,提示其是不适合强化化疗患者的可行选择。
  • 需进一步研究以确定该人群的最佳维奈克拉剂量、化疗组合和药代动力学。

研究设计与样本

  • 回顾性病历审查,纳入在辛辛那提儿童医院医疗中心接受HMA+VEN治疗的儿童及AYA AML患者。
  • 共27例患者接受30个HMA+VEN治疗疗程,其中复发/难治性(R/R)21例,新诊断9例(因不适合强化化疗)。
  • 维奈克拉采用400 mg成人暴露等效剂量(AED),中位治疗持续时间21天(范围7-30天)。

主要发现

  • R/R队列具有高危细胞分子遗传学异常和既往广泛治疗史,18例复发患者中50%(n=9)曾接受造血干细胞移植(HSCT)。
  • 总体CR/CRi率为73%(77%的患者MRD阴性<0.1%),60%的患者后续接受HSCT。
  • 新诊断组(n=9)中89%达到CR/CRi(78% MRD阴性),78%后续接受HSCT。
  • R/R组(n=21)CR/CRi率为67%(71% MRD阴性),52%后续接受HSCT。
  • 3-4级毒性包括中性粒细胞减少(90%)、贫血(64%)、血小板减少(64%)和发热性中性粒细胞减少(44%)。

临床怎么用

  • 作者认为HMA+VEN可作为不适合强化化疗的儿童/AYA AML患者的可行选择。
  • 作者指出需进一步研究以确定该人群的最佳维奈克拉剂量、化疗组合和药代动力学。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is used for adult acute myeloid leukaemia (AML), but its application in paediatric, adolescent and young adult (AYA) AML lacks prospective studies. We performed a retrospective chart review of paediatric and AYA AML patients treated with HMA + VEN at Cincinnati Children's Hospital Medical Centre. Twenty-seven patients received 30 HMA + VEN treatment courses for relapsed/refractory (R/R, n = 21) or newly diagnosed (n = 9) AML due to ineligibility for intensive chemotherapy. The R/R cohort had high-risk cytomolecular genetic alterations and prior extensive treatments, with 50% (n = 9) of relapse patients (n = 18) having undergone haematopoietic stem cell transplantation (HSCT). Venetoclax treatment using the 400 mg adult exposure-equivelant dosing (AED) had a median duration of 21 days (range 7-30 days). Grade 3-4 toxicities included neutropenia (90%), anaemia (64%), thrombocytopenia (64%) and febrile neutropenia (44%). The overall complete remission (CR)/CR with incomplete blood count recovery (CRi) rate was 73% (77% minimal residual disease [MRD] negativity <0.1%), with 60% undergoing HSCT. Among newly diagnosed patients (n = 9), 89% achieved CR/CRi (78% MRD negativity) and 78% proceeded to HSCT. The R/R cohort (n = 21) showed a 67% CR/CRi rate (71% MRD negativity), with 52% undergoing HSCT. These findings support the safety and efficacy of HMA + VEN in paediatric/AYA AML, indicating it as a viable option for patients unfit for intensive chemotherapy. Further studies are necessary to determine optimal venetoclax dosing, chemotherapy combinations and pharmacokinetics in this population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. LeBlanc FR, Breese EH, Burns KC, et al. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. Br J Haematol. 2024. PMID: 39082439. doi:10.1111/bjh.19679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。